Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti cd37 antibodies

a technology of anti-cd37 and antibody molecules, applied in the field of immunotherapies, to achieve the effect of exquisite antigen specificity

Inactive Publication Date: 2014-01-02
BOEHRINGER INGELHEIM INT GMBH
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes an anti-CD37 antibody that has strong cancer-killing activity without the need for cross-linking. This makes it a better option for cancer treatment compared to other antibodies. The antibody can be produced using different expression vectors and can be modified with chemical groups to improve its properties. Overall, the invention provides a valuable tool for research and development of cancer treatment strategies.

Problems solved by technology

However, only a subset of patients respond to therapy and the majority of those eventually relapse following rituximab treatment.
Third, the antibody may alter the ability of B cells to respond to antigen or other stimuli.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti cd37 antibodies
  • Anti cd37 antibodies
  • Anti cd37 antibodies

Examples

Experimental program
Comparison scheme
Effect test

example 2

Chimeric mAb A0 Specifically Recognizes the CD37 Antigen

[0186]The specificity of MAb A0 for cellular CD37 is tested in a FACS competition assay on Ramos Burkitt lymphoma cells (ATCC #CRL-1596). Cells are grown in tissue culture flasks (175 cm2) using RPMI-1640+ GlutaMAX supplemented with 10% heat-inactivated fetal bovine serum, 12.5 mM HEPES, 1 mM sodium pyruvat, 1% MEM non-essential amino acids as culture medium. Cells are cultivated with an initial density of 3×105 cells / ml at 37° C. and 5% CO2 in a humidified atmosphere for three days. The cultures are maintained at a cell concentration between 3×105 and 1.8×106 / ml by sub-cultivation in a ratio of 1:6 with fresh culture medium 2-3 times a week. For FACS competition analysis, the CD37-specific mAb HH1 (Santa Cruz) directly labeled with phycoerythrin (PE) is used at a concentration of 1 μg / ml. The antibody is preincubated with the unlabelled competitor antibody A0 for 10 min at 4° C. at the indicated molar ratio. Thereafter, 1×105 ...

example 3

Binding of Humanized Versions of mAb A0 to Cellular CD37 Antigen

[0187]Humanized versions of A0 are tested for their binding to cellular CD37 antigen by FACS analysis. Antibodies are added to Ramos cells at the indicated concentrations and allowed for binding for 30 min at 4° C. Thereafter, bound antibody is detected with PE-labelled goat-anti-human IgG antibody (Sigma), cells are washed twice with PBS, and thereafter cells are resuspended in FACS buffer and analyzed by FACS on a BD FACS Canto. Examples are shown in FIGS. 2 and 3 (antibodies A, B, C, D, I or A, H, I, J, K, L and M, respectively; see Table 1). Several of the humanized versions of A0 show similar binding to Ramos cells as the parental antibody A0, indicating that humanization does not reduce binding to cellular CD37 antigen.

example 4

FACS Scatchard Analysis of Humanized Versions of Chimeric mAb A0

[0188]The affinity of humanized versions of antibody A0 (designated B, C, D, H, I and K; see Table 1) to cellular CD37 antigen is determined by FACS scatchard analysis as described elsewhere (Brockhoff et al., 1994). Briefly, antibody dilutions are prepared in a 96 well plate starting with 100-400 nM in the first well (80 μA), followed by 11 dilution steps (1:2, 40+40 μl). 50 μl of mAb dilutions are added to FACS tubes, 150 μl cells (0.8×106 / ml=1.2×105 cells / tube) are added to each FACS tube. Cells are gently mixed and incubated for 1 h on ice. Thereafter 50 μl FITC conjugated secondary antibody (conc. 15 μg / ml; mouse mAb anti-hu IgG all subclasses, Zymed 05-4211) is added, mixed, and incubated for 30 min on ice. 4 ml PBS ph7.2 containing 0.02% acid are added thereafter, cells are pelleted and resuspended in 300 μl PBS pH 7.2 and subjected to FACS analysis using a BD FACS Canto. All experimental steps are performed on w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.

Description

INTRODUCTION[0001]The present invention relates to immunotherapies that are based on B cell depletion. In particular, the present invention relates to anti-CD37 antibody molecules for use in such therapies, e.g. in the treatment of B cell malignancies and autoimmune conditions.[0002]Immunotherapy using monoclonal antibodies (mAbs) has been emerging as a safe and selective method for the treatment of cancer and other diseases. In particular, the role of monoclonal antibodies in therapies that are based on B cell depletion, e.g. in the treatment of B cell malignancies, has expanded since the introduction of rituximab (Rituxan®), an antibody that is directed against the CD20 antigen on the B cell surface. Numerous studies have confirmed the efficacy of rituximab as a single agent and in combination therapy in low-grade NHL (Hiddemann et al., 2005a; Hiddemann et al., 2005b; Hainsworth 2004; McLaughlin et al., 1998), mantle cell lymphoma (Forstpointner et al., 2004; Kahl et al., 2006; Fo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/30A61K45/06A61K39/395
CPCC07K16/3061A61K39/39558A61K45/06A01K67/0275A01K2207/15A01K2217/072A01K2227/105A61K2039/505C07K2317/24C07K2317/72C07K2317/92C07K2317/732C07K2317/73C07K16/2896A61P29/00A61P35/00A61P35/02A61P37/00A61P37/02A61P43/00C07K16/28C07K2317/76
Inventor HEIDER, KARL-HEINZBORGES, ERICOSTERMANN, ELINBORG
Owner BOEHRINGER INGELHEIM INT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com